Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 — Stella

Home/Stargardt-Like Macular Dystrophy/Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

View on ClinicalTrials.gov

Recruiting

Back to Stargardt-Like Macular Dystrophy trials

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Sponsor

National Eye Institute (NEI)

Collaborators

National Cancer Institute (NCI)

Enrollment target

~25 participants

Started

April 2022

Primary completion

July 2028

Age range

10 Years – 100 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.